Lv3
340 积分 2023-11-16 加入
Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a retrospective multicenter study of 83 patients
1个月前
已完结
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan
1个月前
已完结
Preoperative MRI-based multiparametric model for survival prediction in hepatocellular carcinoma patients with portal vein tumor thrombus following hepatectomy
1个月前
已完结
Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments
1个月前
已完结
Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein
1个月前
已关闭
Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial
1个月前
已完结
Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial
1个月前
已完结
Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial
1个月前
已完结
Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study
1个月前
已完结
Evolving Strategies in the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Narrative Review of Locoregional and Surgical Therapies
1个月前
已完结
皖公网安备34019202002308
